BiomX names IDF colonel Roy Timor-Rousso as chief business officer May 27, 2026 09:40AM
BiomX subsidiary Zorronet launches mobile command app May 6, 2026 04:17PM
BiomX acquires controlling interest in Israeli defense firm DFSL Apr 13, 2026 09:20AM
BiomX receives NYSE American deficiency notice over equity requirements Mar 27, 2026 04:30PM
BiomX amends warrant terms, explores defense sector opportunities Mar 19, 2026 09:15AM


Mar 9, 2026 10:48AM H.C. Wainwright Downgrades BiomX (PHGE) to Neutral
Feb 13, 2026 04:09PM BiomX appoints new director following board resignations
Jan 27, 2026 01:49PM BiomX addresses unusual stock trading activity
Nov 28, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on BiomX (PHGE)
Nov 12, 2025 04:22PM BiomX Inc. (PHGE) Tops Q3 EPS by 29c
Aug 20, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on BiomX (PHGE)
Aug 19, 2025 08:20AM FDA places clinical hold on BiomX cystic fibrosis drug trial
Aug 13, 2025 08:15AM BiomX Inc. (PHGE) Misses Q2 EPS by 19c
Jul 15, 2025 07:16AM H.C. Wainwright Reiterates Buy Rating on BiomX (PHGE)
Jul 15, 2025 06:13AM H.C. Wainwright Reiterates Buy Rating on BiomX (PHGE)
Jul 14, 2025 09:01AM BiomX doses first patient in Phase 2b cystic fibrosis trial
May 16, 2025 06:45AM BiomX (PHGE) PT Lowered to $15 at H.C. Wainwright
May 15, 2025 04:50PM BiomX Inc. (PHGE) Misses Q1 EPS by 33c
Apr 4, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on BiomX (PHGE)
Apr 1, 2025 06:47AM BiomX (PHGE) PT Raised to $21 at H.C. Wainwright
Mar 31, 2025 06:31AM BiomX Inc. (PHGE) Announces Positive Topline Results from Phase 2 Trial of BX211
Nov 15, 2024 07:28AM H.C. Wainwright Reiterates Buy Rating on BiomX (PHGE)
Aug 16, 2024 02:58PM H.C. Wainwright Reiterates Buy Rating on BiomX (PHGE)
Aug 15, 2024 06:32AM BiomX Inc. (PHGE) Tops Q2 EPS by 16c
Jul 10, 2024 06:31AM BiomX Inc. (PHGE) Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock